⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6364804 | 0.84 | — | — | |
| SCHEMBL3841158 | 0.84 | — | — | |
| SCHEMBL11775307 | 0.81 | — | — | |
| SCHEMBL379946 | 0.81 | — | — | |
| SCHEMBL589076 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL2311189 | 0.78 | — | — | |
| SCHEMBL1855995 | 0.78 | — | — | |
| SCHEMBL584838 | 0.75 | TSHR (0.37) | — | |
| SCHEMBL13834870 | 0.75 | — | — | |
| SCHEMBL9951637 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0743938-A1 | SUBSTITUTED SPIRO COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-11-27 | — | — | EP | claimed |
| WO-1995021817-A1 | SUBSTITUTED SPIRO COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1995-08-17 | — | — | WO | claimed |
| EP-4516778-A1 | COMPOUND SERVING AS DDR1 KINASE INHIBITOR, AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2025-03-05 | — | — | EP | disclosed |
| CN-119421876-A | Compounds and medicaments as DDR1 kinase inhibitors | 日本新药株式会社 | 2025-02-11 | — | — | CN | disclosed |
| WO-2023210599-A1 | COMPOUND SERVING AS DDR1 KINASE INHIBITOR, AND MEDICINE | 日本新薬株式会社 | 2023-11-02 | — | — | WO | disclosed |
| US-11717481-B2 | Reduction of flake-like aggregation in nanoparticulate active agent compositions | ALKERMES PHARMA IRELAND LIMITED (IE) | 2023-08-08 | — | — | US | disclosed |
| US-20220211626-A1 | REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2022-07-07 | — | — | US | disclosed |
| US-20070149591-A1 | Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury | STEPHENSON DIANE T | 2007-06-28 | — | — | US | disclosed |
| US-20060135506-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders | PHARMACIA CORPORATION | 2006-06-22 | — | — | US | disclosed |
| US-20050159419-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage | PHARMACIA CORPORATION (US) | 2005-07-21 | — | — | US | disclosed |
| US-20050159403-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-07-21 | — | — | US | disclosed |
| US-20050085478-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-04-21 | — | — | US | disclosed |
| US-20050080083-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an angiotensin II receptor antagonist for the treatment of central nervous system damage | PHARMACIA CORPORATION (US) | 2005-04-14 | — | — | US | disclosed |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-04-14 | — | — | US | disclosed |
| US-20050075341-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury | PHARMACIA CORPORATION (US) | 2005-04-07 | — | — | US | disclosed |
| US-20050070524-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders | PHARMACIA CORPORATION | 2005-03-31 | — | — | US | disclosed |
| US-20050054646-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders | PHARMACIA CORPORATION | 2005-03-10 | — | — | US | disclosed |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | disclosed |
| US-20050026919-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | disclosed |
| WO-1995030652-A1 | SUBSTITUTED SPIRODIENES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1995-11-16 | — | — | WO | disclosed |